Press Detail

/
PRESS RELEASE

Biotest AG successfully placed a Schuldschein of EUR 210 m.

- Three times oversubscribed due to the significant investor demand

- Further milestone for the financing of the company growth strategy achieved

Dreiech, October 24, 2013 - Biotest successfully placed a Schuldschein of approx. EUR 210 m. Commerzbank Aktiengesellschaft and Landesbank Hessen-Thüringen (Helaba) acted as bookrunners.

Biotest offered 5, 7 and 10 year tranches denominated in EUR as well as 5 year tranches denominated in USD both on a fixed and floating rate basis. Given the strong demand from the market the transaction was significantly oversubscribed and Biotest decided to increase the launch amount of EUR 100 m to some EUR 210 m. All tranches were fixed on the lower end of the spread range.

The transaction has been supported by more than 70 investors, which are mainly saving banks, commercial banks, Landesbanken and also international banks.

The funds raised will be used for the announced capacity expansion project as well as for general business purposes.

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has about 1.800 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart